Katherine Bell-McGuinn, M.D., Ph.D., joins as chief medical officer Company expects to initiate a Phase I clinical trial of its PARG inhibitor ETX-19477 in 2024 SAN DIEGO (BUSINESS WIRE) 858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical.
No. 19 Texas at full strength vs. Texas AM-Corpus Christi sanantoniopost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sanantoniopost.com Daily Mail and Mail on Sunday newspapers.
No. 19 Texas at full strength vs. Texas AM-Corpus Christi batonrougepost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from batonrougepost.com Daily Mail and Mail on Sunday newspapers.